Autopsy report · NCT03498612

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

“Closed per SRC Low Accrual Policy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 6 years 2 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Washington

Sponsor type

University, hospital or other

Conditions

Follicular Lymphoma; Indolent B-Cell Non-Hodgkin Lymphoma; Marginal Zone Lymphoma

Interventions

Laboratory Biomarker Analysis; Pembrolizumab

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Pemetrexed Plus Gemcitabine in Renal Cell Cancer
  “Closed early for poor accrual.” (62% match in meaning)
• Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
  “Low accrual.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.